Abstract. AXL, a receptor tyrosine kinase implicated in cell survival, proliferation, and migration, is also associated with acquired resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor therapy. However, its prognostic significance in lung adenocarcinoma (AD) remains unclear. We therefore evaluated the prognostic significance of the expression of AXL and/or its ligand, growth arrestspecific 6 (GAS6), in completely resected lung AD. We evaluated the relationship between AXL, GAS6, and vimentin expression, as determined by immunohistochemistry (IHC) analysis, with overall survival and disease-free survival in 113 patients with stages I-III lung AD. Protein expression was also assayed using western blot analysis in 10 lung AD cell lines. AXL-positive (AXL
+ status significantly correlated with poor overall survival and disease-free survival, especially in cases with wild-type EGFR. In multivariate analysis, AXL/GAS6 classifications in stage I as well as in stages I-III lung AD were found to be independent factors for poor patient outcomes. Unlike lung AD cell lines with mutant EGFR, almost all cells with wild-type EGFR showed AXL and vimentin co-expression as determined by western blotting. AXL + and GAS6 + expression is relevant to a poor prognosis in resected lung AD patients at stage I. AXL/GAS6 might serve as crucial predictive and prognostic biomarkers and targets to identify individuals at high risk of post-operative death.
Introduction
Lung cancer is the leading cause of cancer-associated deaths worldwide, contributing to approximately 1.4 million deaths each year despite major advances in diagnostics and treatment in the last decade (1) . Approximately 80% of lung cancers are classified histologically as non-small cell lung cancers (NSCLCs), of which the most common type is adenocarcinoma (AD), accounting for approximately half of all NSCLCs (2) . Therapeutic strategies for lung AD patients currently focus on inhibiting target molecules or oncogenic pathways such as receptor tyrosine kinases (3) (4) (5) . Unfortunately, despite initial marked responses to tyrosine kinase inhibitors (TKIs), most AD patients with oncogenic driver mutations eventually acquire resistance. Therefore, identification of predictive and prognostic biomarkers and precision medicine using the biomarkers could have a clinically significant impact on treatment strategies for lung AD patients.
Signaling by AXL, a receptor tyrosine kinase, induces the downstream activation of phosphoinositide 3-kinase (PI3K)/ AKT, signal transducer and activator of transcription 3 (STAT3), mitogen-activated protein kinase (MAPK), and nuclear factor κB (6) (7) (8) . Growth arrest-specific 6 (GAS6) is a ligand of AXL and a member of the vitamin K-dependent protein family. AXL overexpression is associated with cell survival, proliferation, invasion, migration, cell-to-cell adhesion, metastasis, and anti-apoptosis in different types of tumors (9, 10) . In human cancers, increased expression of AXL has been observed in glioma and cancer cells of the breast, stomach and lung, and is associated with invasion and metastasis (11) (12) (13) (14) . Furthermore, recent studies revealed that AXL overexpression led to resistance to EGFR-TKI in NSCLC cells undergoing epithelial-to-mesenchymal transition (EMT), making AXL a potential therapeutic target in patients with acquired resistance to EGFR-TKIs (15, 16) .
In this study, we examined the correlation of AXL and GAS6 expression with clinicopathologic parameters and prognoses in patients with complete lung AD resection. We AXL and GAS6 co-expression in lung adenocarcinoma as a prognostic classifier MASAHIRO with an avidin-biotin complex kit (Funakoshi Co., Ltd., Tokyo, Japan). Finally, slides were exposed to 3, 3'-diaminobenzidine tetrahydrochloride (Muto Pure Chemicals Co., Ltd., Tokyo, Japan), followed by counterstaining with Mayer's hematoxylin. Negative control slides were prepared by omitting the primary antibody in the above steps.
Evaluation of immunohistochemical expression of AXL, GAS6
, and vimentin. IHC scoring was performed using a Histoscore (H-score) as previously described (21), where the staining intensity was graded as follows: 0 (none), 1 (weak), 2 (moderate), and 3 (strong) Western blotting. Western blotting was performed as previously described (23, 24) . Protein samples (10 µg) were separated by SDS-PAGE, transferred to nitrocellulose membranes and incubated in solutions of primary antibodies: anti-AXL (#AF154, Rot: DMG0514051), anti-GAS6 (#Ab885, Rot: DNH0113121), anti-vimentin (#3932, Rot: 3) and β-actin (#A5316, Rot: 123M4876). Anti-β-actin was obtained from Sigma-Aldrich. Anti-goat antibody for AXL and GAS6, anti-rabbit antibody for vimentin or anti-mouse antibody for β-actin were used as secondary antibodies (1:5000 dilution; Vector Laboratories). Proteins were detected with Clarity™ ECL Western blotting Substrate (bio-Rad Laboratories, Inc., Hercules, CA, USA) and visualized using a chemiluminescence system (GE Healthcare Japan Corp., Tokyo, Japan). plus AXL -/GAS6 + plus AXL -/GAS6 -) showed the presence of EGFR mutations, although the difference was not statistically significant (P=0.354; Fig. 2F ). This suggested that high expression levels of AXL and GAS6 were associated with vimentin overexpression and a wild-type EGFR status. Fig. 3C ). These results suggested that AXL and GAS6 co-expression Fig. 3E and F) . In stage I patients with wild-type EGFR, the overall survival and DFS rates for AXL + /GAS6 + patients were also significantly shorter than those for the other patients (P=0.0001 and P=0.0004, respectively; Fig. 3G and H) . In contrast, AXL + /GAS6 + as a negative prognostic factor was not observed in stage I patients with mutant EGFR (data not shown). Thus, AXL and GAS6 expression in combination significantly correlated with a poor outcome for stage I lung AD and an EGFR wild-type status.
The impact of AXL/GAS6 expression on lung AD patient survival. We finally evaluated whether the prognostic ability of AXL + /GAS6 + was affected by underlying clinicopathological covariates using univariate and multivariate Cox regression analyses. Among stages I-III patients, N factor [hazard ratio (HR)=2.94, P=0.002], p-stage (HR=2.61, P=0.007) and AXL/GAS6 classification (HR=2.56, P=0.011) were significant predictors of survival in univariate analysis (Table II) . Multivariate analysis, adjusted for N factor, p-stage, and AXL/GAS6 classification, showed that only AXL + /GAS6 + (HR=2.45, P=0.018) was a statistically significant predictor of survival (Table II) . In stage I cases, univariate analysis showed that the EGFR mutation status (HR=6.22, P=0.001) and AXL/GAS6 classification (HR=3.89, P=0.012) were significantly associated with death. Finally, the EGFR mutation status (HR=9.30, P=0.0001) and AXL/GAS6 classification (HR=5.90, P=0.0024) were found to be independent predictors of death in multivariate analysis (Table II) . Thus, co-expression of AXL and GAS6 significantly correlated with death for stages I-III and I lung AD patients.
AXL, GAS6, and vimentin expression in lung AD cell lines.
We also evaluated protein expression levels of AXL, GAS6, and vimentin in 10 lung AD cell lines (Fig. 4) . Unfortunately, GAS6 proteins were not detected in cells, probably because this is a secreted protein. Among seven AD cell lines with wild-type EGFR, five cell lines (A549, RERF-LC-KJ, RERF-LC-MS, PC-14, and LC-2/ad) strongly expressed AXL and vimentin protein.
Of three mutant EGFR cell lines, PC-9 and H1975 showed strong AXL and vimentin expression, respectively.
Discussion
In this study, we found that the positive expression of AXL and GAS6 in combination could be used as a marker of a poor prognosis in lung AD patients. AXL protein expression has, Table II . Univariate and multivariate Cox proportional hazards models of factors associated with death in stages I-III and stage I patients. in the past, correlated with lymph node metastasis and clinical stage (13, 25) , while high expression levels of AXL and GAS6 have been associated with poor survival in lung AD patients with stage I-III (25) . Consistent with these findings, we observed that AXL and GAS6 expression levels significantly correlated with poor survival in lung AD cases. Furthermore, we showed the negative impact that the high expression of both AXL and GAS6 had on the survival of patients with stage I lung AD. Of note, AXL + expression significantly correlated with vimentin + expression, as reported in an earlier in vitro study (26) . The co-expression of AXL and GAS6 was mostly associated with vimentin positive expression in this study. Thus, rather than the individual expression of either protein, the expression of both in combination may be more closely associated with the biological features of vimentin, suggesting that AXL + /GAS6 + tumor cells may represent abundant vimentin. Vimentin may actually induce AXL expression (27) . However, vimentin expression was not a prognostic factor in this study. besides vimentin, AXL expression could be also regulated by other factors, including TGF-β1 (26) . Therefore, AXL and GAS6 co-expression, but not vimentin expression, may be critical for patient survival, as well as in the carcinogenesis of lung AD. Furthermore, high vimentin expression correlated with an EGFR wild-type status. AXL and vimentin-positive expression were also found for most AD cell lines showing wild-type EGFR. Therefore, AXL and GAS6 may play a critical role in tumor progression and patient survival in lung AD patients with wild-type EGFR. As for the significance of AXL/GAS6/vimentin for the EGFR mutant-type, small numbers of stage I-III AD patients as well as AD cells with the EGFR mutation have been analyzed. Further studies are planned to perform using large-scale samples with an EGFR mutation, including stage IV, to evaluate the correlation between AXL/GAS6/vimentin expression and EGFR status as a prognostic factor.
Univariate analysis Multivariate analysis
Recently, AXL upregulation and activation by GAS6 has been implicated in the EMT of breast cancer and hepatocellular carcinoma (28, 29) . Likewise, the expression of both AXL and GAS6 is deemed to be closely related to full-blown EMT in a subset of lung AD. AXL-related EMT resulting in drug resistance has been reported in patients with prior EGFR-TKI therapy, as well as in in vitro studies using NSCLC cell lines (15, 16, 30) . Aberrant AXL signaling and the development of the EMT phenotype were also associated with ALK inhibitor resistance in ALK-driven neuroblastoma cells (31) . Our clinical data support the concept that EMT under AXL or GAS6 high expression apparently exists in patients with prior surgical resection for lung AD, which consequently leads to de novo resistance to EGFR-TKI (15, 30) .
Unfortunately, approximately 20-30% of early stage NSCLC patients undergo a relapse, even after complete surgical treatment (32) . Sensitive biomarkers can help identify patients with early-stage or locally advanced NSCLC who have a high risk of relapse and a poor prognosis. High expression levels of excision repair cross-complementation group 1 (ERCC1), ribonucleotide reductase subunit M2 (RRM2), and thymidylate synthase (TS) were suggested as negative prognostic factors for patients with resected NSCLC (33, 34) . In addition, cyclooxygenase-2 and amplification of the actin-4 (ACTN4) gene were considered markers for a poor prognosis in stage I disease (35, 36) . However, a conceivable prognostic biomarker for patients with stage I AD has not yet been established. In the present study, we demonstrated that the co-expression of AXL and GAS6 had a greater effect on survival in patients with stage I lung AD, especially in those with wild-type EGFR. AXL has been recognized as a potential therapeutic target for overcoming EGFR-TKI resistance (30) . The bATTLE study using AXL inhibitor and EGFR-TKI demonstrated synergistic effects in some patients with wild-type EGFR (15) . Our findings suggest that the combination of AXL and GAS6 was significantly associated with poor overall survival and DFS in the AD subgroup of stage I disease with wild-type EGFR. Therefore, AXL and GAS6 may be promising predictive biomarkers of a drug response and crucial therapeutic targets in lung AD with wild-type EGFR. The prognostic significance of the co-expression of AXL and GAS6 needs to be further validated in large-scale studies of AD samples. Further investigation is also needed to determine whether the overexpression of AXL and/or GAS6 modulate different internal signaling pathways, depending on the EGFR status and EMT signature.
Our study demonstrated that the co-expression of AXL and GAS6 in a tumor was a significant independent predictor of a poor outcome in patients with stage I lung AD, as well as stages I-III lung AD. An AXL and GAS6 expression status may be useful for the identification of lung AD patients at high risk of post-operative death and who will benefit from adjuvant chemotherapy.
